The NDA was submitted for investigational muscarinic antipsychotic, KarXT (xanomeline-trospium), which functions as a dual M1/M4 muscarinic acetylcholine receptor agonist within the central nervous system.
Erin O'Brien
Advertisement
Articles by Erin O'Brien
United States leaders work together to create bipartisan solutions for the youth mental health crisis.
Risk of suicide attempt is higher among adults, women.
Survey results addressed connections between migraine and mental health, stigma, and treatment preferences.
The warnings cite consumer risks and Food, Drug and Cosmetics Act violations.
Recent research supports evidence for long-term impairment in memory, executive function.
Results highlight the impact of education on patient understanding of potential adverse events.
Catch up on all the latest in ADHD from the virtual APSARD 2022 Annual Meeting.
What are the connections between ADHD, infectious diseases, and COVID-19?
Advertisement
Latest Updated Articles
Spotlight: Issues in ADHDFebruary 23rd 2022
NDA for Investigational Schizophrenia Treatment Submitted to FDAOctober 2nd 2023
Advertisement
Advertisement
Trending on Drug Topics
1
The Drug Price Paradox: PBMs, Pharmacies, and the Path to Affordability
2
Zepbound Lowers Health Care Costs in Older Adults With Obesity
3
How mRNA and Protein-Based COVID-19 Vaccines Work
4
Updated Guideline Refines Approach to Migraine Prevention in Adults
5